source
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
- FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risksA Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…